Results from a trial on the use of the monoclonal antibody canakinumab in heart disease has failed to impress, but an exploratory analysis suggests it may have a role in lung cancer. The trial was not designed to explore the benefits of cancer, but the fact that a mortality benefit from cancer was observed may ...
Heart trial finds lung cancer benefit
By Larry Husten
30 Aug 2017